Palliative Hepatic Arterial Infusion in Renal Cell Carcinoma Spreading to the Liver: A Retrospective Analysis

Venook A.P. , Warren R.S. : Regional chemotherapy approaches for primary and metastatic liver tumors. Surg Oncol Clin N Am, 5: 411–427, 1996.

Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst, 88: 252–258, 1996.

Yagoda A. , Petrylak D. , Thompson S. : Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin N Am, 20: 303–321, 1993.

Mavligit G.M. , Zukivski A.A. , Gutterman J.U. , Salem P. , Charnsangavej C. , Wallace S. : Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases. J Clin Oncol, 8: 319–324, 1990.

Melichar B. , Touskova M. , Blaha M. , Vesely P. , Dvorak J. , Krajina A. , Cerman J. : Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biother Radiopharm, 17: 545–552, 2002.

Melichar B. , Voboril Z. , Cerman J. , Melicharova K. , Mergancova J. , Voboril R. , Jandik P. : Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy. Hepatogastroenterology, 53: 422–430, 2006.

Barkholt L. , Danielsson R. , Calissendorff B. , Svensson L. , Malihi R. , Remberger M. , Uzunel M. , Thorne A. , Ringden O. : Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. Transplantation, 78: 697–703, 2004.

Fisher R.I. , Rosenberg S.A. , Sznol M. , Parkinson D.R. , Fyfe G. : High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am, 3: S70–S72, 1997.

McDermott D.F. , Regan M.M. , Clark J.I. , Flaherty L.E. , Weiss G.R. , Logan T.F. , Kirkwood J.M. , Gordon M.S. , Sosman J.A. , Ernstoff M.S. , Tretter C.P.G. , Urba W.J. , Smith J.W. , Margolin K.A. , Mier J.W. , Gollob J.A. , Dutcher J.P. , Atkins M.B. : Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol, 23: 133–141, 2005.

Yang J.C. , Sherry R.M. , Steinberg S.M. , Topalian S.L. , Schwartzentruber D.J. , Hwu P. , Seipp C.A. , Rogers-Freezer L. , Morton K.E. , White D.E. , Liewehr D.J. , Merino M.J. , Rosenberg S.A. : Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol, 21: 3127–3132, 2003.

Huland E. , Heinzer H. , Mir T.S. , Huland H. : Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience. Cancer J Sci Am, 3: S98–S105, 1997.

Wirth M.P. : Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am, 20: 283–295, 1993.

Murray Law T. , Motzer R.J. , Mazumdar M. , Sell K.W. , Walther P.J. , O'Connell M. , Khan A. , Vlamis V. , Vogelzang N.J. , Bajorin D.F. : Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer, 76: 824–832, 1995.

Motzer R.J. , Hutson T.E. , Tomczak P. , Michaelson M.D. , Bukowski R.M. , Rixe O. , Oudard S. , Negrier S. , Szcylik C. , Kim S.T. , Chen I. , Bycott P.W. , Baum C.M. , Figlin R.A. : Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 356: 115–124, 2007.

Childs R. , Chernoff A. , Contntin N. , Bahceci E. , Schrump D. , Leitman S. , Read E. , Tisdale J. , Dunbar C. , Linehan W.M. , Young N.S. , Barrett A.J. : Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med, 343: 750–758, 2000.

Rini B.I. , Zimmerman T. , Stadler W.M. , Gajewski T.F. , Vogelzang N.J. : Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol, 20: 2017–2024, 2002.